Top

RSV is a highly contagious virus that causes infections in the respiratory tract.  RSV infects nearly every child at least once by the age of two and is a major cause of hospitalization due to respiratory infection in young children, the elderly and immunocompromised patients.  RSV infections can lead to serious respiratory complications, such as croup, pneumonia and bronchiolitis, as well as, in extreme cases, death. In the United States, an estimated 2.1 million children under the age of five with RSV infection require medical attention each year, and of these, approximately 60,000 are hospitalized.  In the elderly and high-risk adult populations in the United States, RSV infection accounts for an estimated 180,000 hospitalizations and 14,000 deaths per year. Globally, RSV is responsible for 34 million acute lower respiratory infections, 3.4 million hospitalizations, and 200K deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.

 

ASN500

Our ASN500 program, comprised of highly potent mAbs targeting RSV, is currently in its lead-optimization phase.  We believe ASN500, which we are developing for the prevention of RSV infection, has the potential to offer benefits over existing preventive therapies in terms of potency, dosing strategy, route of administration and the way in which the drug is manufactured, to better serve both new and existing target populations globally.